A Study of an Integrated Approach to Treating Recurrent Lung Adenocarcinomas Resistant to Tyrosine Kinase Inhibitors
Tab Title Description
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Rochester, Minnesota: 14-002084
NCT ID: NCT02616211
Sponsor Protocol Number: 14-002084
About this study
The purpose of this study is identify molecular changes in recurring lung cancer tumors, and to determine the most significant genes, pathways and clinical characteristics in these lung adenocarcinomas which are resistant to tyrosine kinase inhibitor.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
- 18 years or older
- Lung adenocarcinoma tumors positive for any targetable genetic alterations
- Have shown by CT/PET scan a partial or no response, progression or recurrence while on or after gene targeted therapy
- Tumor is accessible for biopsy or surgery
- Expected life is 6 months or longer
- < 18 years
- Lung cancer other than adenocarcinoma
- Not able to communicate in English
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
|Mayo Clinic Location
Mayo Clinic principal investigator
Jin Jen, M.D., Ph.D.
Closed for enrollment
Publications are currently not available